Updated July 2010
This is a list of all the key drugs covered under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001. It is based on the Home Office document List of Drugs Currently Controlled under the Misuse of Drugs Legislation.
The Home Office table could be improved in a number of areas; it wasn't clear from the table which substances were specified directly by the MDA, and by mixing up brands, direct MDA entries and analogues the table was hard to relate to the legislation. It was also not up to date.
A number of changes have been made to the table including reformatting, adding columns for other drug names, drug types and notes.
The table has been updated to include changes made since March 2010.
The List (should) include all specific drugs listed in the Misuse of Drugs Act 1971. It also includes substances not specifically mentioned in the Act but which are covered by the various analogue clauses.
The text of the relevant sections of the Misuse of Drugs Act and the Misuse of Drugs Regulations is available on this site and can be accessed via the Home Office website and the OPSI website.
There will inevitably be errors and omissions in this table; it should therefore only be used for guidance and should not be considered a definitive interpretation of the current legal status of drugs in the UK.
Most importantly, the ABSENCE of a substance from the table does not mean it is legal as it may be covered by an analogue clause.
No liability can be accepted for criminal proceedings arising from the information in this table.
Drug Facts:
Drug | AKA | Class | Sch | Type | Notes |
(Coloured entries: as
listed in MDA) |
Other chemical names |
(MDA) |
(MDR ’01) |
|
|
Acetorphine |
|
A |
2 |
Opioid |
|
Acetyldihydrocodeine |
|
B |
2/5 |
Opioid |
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie
Class A) if in a preparation designed for administration by injection. Falls within Schedule 5 if in a preparation either alone or with one or more of the drugs referring to this note not being a preparation designed for administration by injection, when compounded with one or more active or inert ingredients and containing a total of not more than 100 mg of the substance or substances (calculated as base) per dosage unit or with a total of not more than 2.5% (calculated as base) in undivided preparations. |
Acetylihydrocodeinone |
|
B |
2 |
Opioid |
In Home Office list – may be a typo |
Alfentanil |
|
A |
2 |
Opioid |
|
Allobarbital |
|
B |
3 |
Barbiturate |
|
Allobarbitone |
|
B |
3 |
Barbiturate |
|
Allyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
Allylprodine |
|
A |
2 |
opioid |
|
Alpha Methyl Fentanyl |
|
A |
1 |
Opioid |
Para (d) |
Alpha,Alpha-Dimethyl-3,4-methylenedioxyphenethyl (methyl)amine |
|
A |
1
|
Phenylethylamine family |
|
Alpha,Alpha-Dimethyl-3,4-methylenedioxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
|
Alpha-3-Acetoxy-6-Methylanino-4,4-Diphenylheptane |
|
A |
2 |
Opioid |
Covered by analogue clauses |
Alphacetyl Methadol |
|
A |
2 |
Opioid |
|
Alphacetylmethadol |
|
A |
2 |
Opioid |
|
Alphameprodine |
|
A |
2 |
Opioid |
|
Alphamethadol |
|
A |
2 |
Opioid |
|
Alpha-Methyl-4-(methylthio)phenethylamine |
4-methylthioamphetamine |
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
Alpha-Methylfentanyl |
|
A |
1 |
Opioid |
Para 1(d) |
Alphaprodine |
|
A |
2 |
Opioid |
|
Alphenal (5-Ally-5-Phenylbarbituric Acid) |
|
B |
3 |
Barbiturate |
|
Alprazolam |
|
C |
4 Pt 1 |
Benzo |
|
a-Methyl-3,4 methylenedioxyphenethyl(prop-2-ynyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
a-methylphenethylhydroxylamine |
N-Hydroxyamphetamine |
B |
2 |
Amphetamine |
SI 2001/3932 |
a-Methylphenethylhydroxylamine |
N-Hydroxyamphetamine |
B |
2 |
Amphetamine |
|
Aminorex |
|
C |
4 Pt 1 |
Stimulant |
|
Amphetamine |
Amphetamine Sulphate |
B |
2 |
Amphetamine |
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection. |
Amylobarbitone |
|
B |
3 |
Barbiturate |
|
Androst-4-ene-3,17-diol |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Anhydroecgonine HCL |
|
A |
2 |
Cocaine derivative |
|
Anhydroecgonine Methyl |
|
A |
2 |
Cocaine derivative |
|
Anileridine |
|
A |
2 |
Analgesic |
|
Any 5,5 disubstituted barbituric acid |
|
B |
3 |
Barbiturate |
|
Aprobarbital |
|
B |
3 |
Barbiturate |
|
Aprobarbitone |
|
B |
3 |
Barbiturate |
|
Atamestane |
|
C |
4 Pt 2 |
Aromatase Inhibitor |
|
Barbital |
|
B |
3 |
Barbiturate |
|
Barbitone |
|
B |
3 |
Barbiturate |
|
Barbituric acid, (any 5,5 disubstituted) |
|
B |
3 |
Barbiturate |
|
Benzethidine |
|
A |
2 |
Opioid |
|
Benzodioxolylbutanamine |
BDB |
A |
1 |
Phenylethylamine family |
|
Benzoylecgonine-Isopropyl Ester |
|
A |
2 |
Cocaine derivative |
|
Benzphetamine |
|
C |
3 |
Amphetamine |
|
Benzyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
Benzylmorphine (3-benzylmorphine) |
|
A |
2 |
Opioid |
|
Betacetylmethadol |
|
A |
2 |
Opioid |
|
Betameprodine |
|
A |
2 |
Opioid |
|
Betamethadol |
|
A |
2 |
Opioid |
|
Betaprodine |
|
A |
2 |
Opioid |
|
Bezitramide |
|
A |
2 |
Analgesic |
|
Bolandiol |
|
C |
4 Pt 2 |
Steroid |
|
Bolasterone |
|
C |
4 Pt 2 |
Steroid |
|
Bolazine |
|
C |
4 Pt 2 |
Steroid |
|
Boldenone |
|
C |
4 Pt 2 |
Steroid |
|
Boldione |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Bolenol |
|
C |
4 Pt 2 |
Steroid |
|
Bolmantalate |
|
C |
4 Pt 2 |
Steroid |
|
Bromazepam |
|
C |
4 Pt 1 |
Benzo |
|
Bromo-STP |
4-Bromo-2,5-dimethoxyamphetamine |
A |
1 |
Phenylethylamine family |
|
Bufotenine |
|
A |
1 |
Tryptamine – hallucinogen |
|
Buprenorphine |
Temgesic |
C |
3 |
Opioid |
|
Butalbarbital |
|
B |
3 |
Barbiturate |
|
Butalibtal (Fiorinal) |
|
B |
3 |
Barbiturate |
|
Butallylonal |
|
B |
3 |
Barbiturate |
|
Butethal |
|
B |
3 |
Barbiturate |
|
Butobarbital |
|
B |
3 |
Barbiturate |
|
Butobarbitone |
|
B |
3 |
Barbiturate |
|
Calusterone |
|
C |
4 Pt 2 |
Steroid |
|
Camazepam |
|
C |
4 Pt 1 |
Benzo |
|
Cannabinol |
|
B |
1 |
Cannabinoid |
|
Cannabinol derivatives |
|
B |
1 |
Cannabinoids |
|
Cannabis and cannabis resin |
Cannabis |
B |
1 |
Cannabinoids |
|
Carfentanil |
|
A |
2 |
Opioid |
|
Cathine |
norpseuodephedrine |
C |
3 |
Cathinone family |
|
Cathinone |
|
C |
1 |
Cathinone family |
Active ingredient in Chat |
Cathinone derivatives |
|
B |
1 |
Cathinone family |
|
Cense Dal neal Barbitone |
|
B |
3 |
|
In Home Office Table, but possibly a typo |
Chlordiazepoxide |
|
C |
4 |
Benzo |
|
Chlorphentermine |
|
C |
3 |
|
|
Chorionic gonadotrophin |
HCG |
C |
4 Pt 2 |
Steroid |
Para 1(e) |
Clenbuterol |
|
C |
4 Pt 2 |
Steroid |
Para 1(e) |
Clobazam |
|
C |
4 Pt 1 |
Benzo |
|
Clonazepam |
|
C |
4 pt 1 |
Benzo |
|
Clonitazene |
|
A |
2 |
Opioid |
|
Clorazepic acid |
|
C |
4 Pt 1 |
Benzo |
|
Clostebol |
|
C |
4 Pt 2 |
Steroid |
|
Clotiazepam |
|
C |
4 Pt 1 |
Steroid |
|
Cloxazolam |
|
C |
4 Pt 1 |
Steroid |
|
Coca leaf |
|
A |
1 |
Cocaine |
|
Cocaethylene |
|
A |
1 |
Cocaine Derivative |
|
Cocaine |
Cocaine Hydrochloride |
A |
2 |
Cocaine |
|
Codeine |
|
B |
2/5 |
Opiate |
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection. |
Codeine Linctus |
|
B |
5 |
Opiate |
|
Co-Proxamol |
dextropropoxyphene |
C |
2/5 |
Opiate |
|
Cyclobarbital |
|
B |
3 |
Barbiturate |
|
Cyclobarbitone |
|
B |
3 |
Barbiturate |
|
Cyclobarbitone calcium |
|
B |
3 |
Barbiturate |
|
Cyclopentobarbitone |
|
B |
3 |
Barbiturate |
|
Cyclopropylmethyl(α-methyl-3,4-methylenedioxyphenethyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
D3-Morphine |
|
A |
2 |
Opiate |
para 1 |
Danazol |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
D-DL-3-Acetoxy-6-methylamino-4,4-diphenyl heptane |
|
A |
2 |
Opioid |
|
Delorazepam |
|
C |
4 Pt 1 |
Benzo |
|
Delta-1-Tetrahydrocannabinol |
|
B |
1 |
Cannabinoid |
|
Delta-8-Tetrahydrocannabinol (or Delta-8-THC) |
|
B |
1 |
Cannabinoid |
|
Delta-9-Tetrahydrocannabinol (or Delta-9-THC) |
THC |
B |
1 |
Cannabinoid
|
|
Delta-Tetrahydrocannabinol – D3 |
|
B |
1 |
Cannabinoid |
para 1(c) |
Deoxyephedrine Hydrochloride |
|
B |
2 |
Stimulant |
para 6 |
Desomorphine |
|
A |
2 |
Opioid |
|
Desoxymethyltestosterone |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Dexamphetamine Sulphate |
Dexedrine |
B |
2 |
Amphetamine |
para 6 |
Dextromoramide |
|
A |
2 |
Opioid |
|
Dextropropoxyphene |
|
C |
2/5 |
Opioid |
within Schedule 5 if in a preparation designed for oral administration,
containing not more than 135 mg of dextropropoxyphene (calculated
as base) per dosage unit or with a concentration of not more than
2.5% (calculated as base) in undivided preparations.
|
Dexyephedrine |
|
B |
2 |
Stimulant |
|
Diallybarbituric Acid |
|
B |
3 |
Barbiturate |
|
Diamorphine |
Diacetylmorphine |
A |
2 |
Opioid |
|
Diapromide |
|
A |
2 |
Opioid |
|
Diazepam |
Valium |
C |
4 Pt 1 |
Benzo |
|
Diethylpropion |
|
C |
3 |
Stimulant |
Amphetamine-like effect used in dieting |
Diethylthiambutene |
|
A |
2 |
|
|
Difenoxin |
(1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid) |
A |
2/5 |
Opiate |
Falls within Schedule 5 if in any preparation of difenoxin containing, per dosage unit, not more than 0.5 mg of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin. |
Dihydrocodeine |
DF118 |
B |
2/5 |
Opioid |
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection. Falls within Schedule 5 if in a preparation either alone or with one or more of the drugs referring to this note not being a preparation designed for administration by injection, when compounded with one or more active or inert ingredients and containing a total of not more than 100 mg of the substance or substances (calculated as base) per dosage unit or with a total of not more than 2.5% (calculated as base) in undivided preparations. |
Dihydrocodeinone-0-carboxymethyloxime |
|
A |
2 |
Opioid |
|
Dihydroetorphine |
|
A |
2 |
|
SI 2003/1243 |
Dihydromorphine |
|
A |
2 |
Opioid |
|
Dihydromorphine 3,6-Diglucuronide |
|
A |
2 |
Opioid |
|
Dimenoxadole |
Estosin |
A |
2 |
Opioid |
|
Dimepheptanol |
|
A |
2 |
Opioid |
|
Dimethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
Dimethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine |
|
A |
1 |
Ectsasy family |
|
Dimethylthiambutene |
|
A |
2 |
Opioid |
|
Dioxaphetyl butytate |
|
A |
2 |
Opioid |
|
DI-P-Chloro Methamphetamine |
|
B |
1 |
Amphetamine |
para 1(c) |
DI-P-Chloroamphetamine |
|
B |
|
Amphetamine |
1 para 1(c) |
Diphenoxylate |
|
A |
2/5 |
Opioid |
Falls within Schedule 5 if in any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 mg of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate. |
Dipipanone |
|
A |
2 |
Opioid |
|
DL-L-Phenyl-2-Aminopropane |
Dietamine |
B |
2 |
Amphetamine |
|
D-Lysergic Acid Methyl Proplamide |
|
A |
1 |
LSD-family |
para (a) |
D-Lysergic Acid N-(Methylopropyl) Amide |
|
A |
1 |
LSD-family |
|
D-Norpseudoephidrine |
|
C |
3 |
Stimulant |
|
Dronabinol (Delta-9-THC) |
Marinol |
B |
2 |
Cannabinoid |
|
Drostanolone |
|
C |
4 Pt 2 |
Steroid |
|
Drotebanol (3,4-dimethoxy-17-methylmorphinan- 6β, 14-diol) |
|
A |
2 |
Opioid |
|
Ecgonine (& any derivative of ecgonine which is convertible to ecgonine or to cocaine) |
|
A |
2 |
Cocaine derivative |
|
Enantiomer d-threo-methylphenidate |
|
B |
2 |
Stimulant |
|
Enestebol |
|
C |
4 Pt 2 |
Steroid |
|
Epitiostanol |
|
C |
4 Pt 2 |
Steroid |
|
Estazolam |
|
C |
4 Pt 1 |
Benzo |
|
Ethchlorvynol |
|
C |
3 |
Sedative |
|
Ethinamate |
|
C |
3 |
Sedative |
|
Ethnine |
Pholcodine |
B |
2/5 |
Opiate |
|
Ethyl loflazepate |
|
C |
4 Pt 1 |
Benzo |
|
Ethyl-l-(3-hydroxy-3-phenlpropyl)-4-phenylpiperidine-4-carboxylate |
|
A |
2 |
Opioid |
|
Ethylmethylthiambutene |
|
A |
2 |
Opioid |
|
ethylmorphine |
3-ethylmorphine |
B |
2/5 |
Opioid |
|
Ethylmorphine (3-ethylmorphine) |
|
B |
2 |
Opioid |
Falls within Schedule 5 if in a preparation either alone or with one or more of the drugs referring to this note not being a preparation designed for administration by injection, when compounded with one or more active or inert ingredients and containing a total of not more than 100 mg of the substance or substances (calculated as base) per dosage unit or with a total of not more than 2.5% (calculated as base) in undivided preparations. Falls within Schedule 5 if in a preparation designed for oral administration, containing not more than 135 mg of dextropropoxyphene (calculated as base) per dosage unit or with a concentration of not more than 2.5% (calculated as base) in undivided preparations. |
Ethyloestrenol |
|
C |
4 Pt 2 |
Steroid |
|
Eticyclidine |
|
A |
1 |
Dissassociative anaesthetic |
|
Etonitazene |
|
A |
2 |
Opioid |
|
Etorphine |
|
A |
2 |
Opioid |
|
Etoxeridine |
|
A |
2 |
Opioid |
|
Etryptamine |
|
A |
1 |
Hallucinongen |
|
Fencamfamin |
|
C |
4 Pt 1 |
stimulant |
|
Fenethylline |
|
C |
2 |
Stimulant |
|
Fenproporex |
|
C |
4 Pt 1 |
stimulant |
|
Fentanyl |
Durogestic |
A |
2 |
Opioid |
|
Flucliazepam |
|
C |
4 Pt 1 |
Benzo |
|
Flunitrazepam |
Rohypnol |
C |
3 |
benzo |
|
Fluoxymesterone |
|
C |
4 Pt 2 |
Steroid |
|
Flurazepam |
|
C |
4 Pt 1 |
Benzo |
|
Formebolone |
|
C |
4 Pt 2 |
Steroid |
|
Fungus (of any kind) which contains psilocin or an ester of psilocin |
|
A |
1 |
Hallucinogen |
|
Furazabol |
|
C |
4Pt 2 |
Streroid |
|
Furethidine |
|
A |
2 |
Opiate |
|
Gamma-butyrolactone (for human ingestion) |
GBL |
C |
|
Depressant |
|
Gamma-hydroxybutyrate |
GHB |
C |
4 Pt1 |
Depressant |
|
Gestrinone |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Glutethimide |
|
B |
2 |
Sedative |
|
Halazepam |
|
C |
4 Pt 1 |
Benzo |
|
Haloxazolam |
|
C |
4 Pt 1 |
Benzo |
|
Heptobarbitone |
|
B |
3 |
Barbiturate |
|
Hexadeuterated Diamorphine |
|
A |
2 |
Opioid |
|
Hexethal sodium |
|
B |
3 |
Sedative |
|
Homoveratrylamine or 2 (3,4-dimelhoxyphenyl) |
|
A |
1 |
Hallucinogen |
|
Hydrocodone |
|
A |
2 |
Opioid |
|
Hydromorphinol |
|
A |
2 |
Opioid |
|
Hydromorphone |
Hydromorphan |
A |
2 |
Opioid |
|
Hydroxypethidine |
|
A |
2 |
Opioid |
|
Ibomal |
Propallylonal |
B |
3 |
Barbiturate |
|
Isocodeine |
|
B |
2 |
Opioid |
|
Isomethadone |
|
A |
2 |
Opioid |
|
Ketamine |
Ket, Special K |
C |
4 Pt 1 |
Dissassociative Anaesthetic |
|
Ketazolam |
|
C |
4 Pt 1 |
Benzo |
|
Ketobemidone |
Cliradon |
A |
2 |
Opioid |
|
Lefetamine |
|
B |
2 |
Opioid |
|
Lero-a-acetylmethadol |
|
A |
2 |
Opioid |
|
Levo-a-acetylmethadol Alpha Methadyl Aceate |
|
A |
2 |
Opioid |
|
Levomethorphan |
|
A |
2 |
Opioid |
|
Levomoramide |
|
A |
2 |
Opioid |
|
Levophenacylmorphan |
|
A |
2 |
Opioid |
|
Levorphanol |
|
A |
2 |
Opioid |
|
Lofentanil |
|
A |
2 |
Opioid |
|
Loprazolam |
|
C |
4 Pt 1 |
Benzo |
|
Lorazepam |
|
C |
4 Pt 1 |
Benzo |
|
Lormetazepam |
|
C |
4 Pt 1 |
Benzo |
|
Lysergamide |
|
A |
1 |
Hallucinogen |
|
Lysergic Acid N-(Methylopropyl) Amide |
|
A |
1 |
Hallucinogen |
|
Lysergic Acid N, N Methylpropylamide |
|
A |
1 |
Hallucinogen |
|
Lysergide and other N-alkyl derivatives of lysergamide |
|
A |
1 |
Hallucinogen |
|
Mazindol |
|
C |
3 |
Stimulant |
|
Mebolazine |
|
C |
4 Pt 2 |
Benzo |
|
Mecloqualone |
|
B |
2 |
Sedative |
|
Medazepam |
|
C |
4 Pt 1 |
Benzo |
|
Mefenorex |
|
C |
4 Pt 1 |
Stimulant |
|
Meperidinic Acid |
|
A |
1 |
Opiate |
|
Mephentermine |
|
C |
3 |
Stimulant |
|
Mephobarbital |
|
B |
3 |
Barbiturate |
|
Mepitiostane |
|
C |
4 Pt 2 |
Steroid |
|
Meprobamate |
|
C |
3 |
Sedative |
|
Mesabolone |
|
C |
4 Pt 2 |
Steroid |
|
Mescaline |
|
A |
1 |
Hallucinogen |
|
Mestanolone |
|
C |
4 Pt 2 |
Steroid |
|
Mesterolone |
|
C |
4 Pt 2 |
Steroid |
|
Metazocine |
|
A |
2 |
Opioid |
|
Methadone |
Adanon |
A |
2 |
Opioid |
|
Methadyl acetate |
|
A |
2 |
Opioid |
|
Methandienone |
|
C |
4 Pt 2 |
Steroid |
|
Methandriol |
|
C |
4 Pt 2 |
Steroid |
|
Methaqualone |
Mandrax |
B |
2 |
Sedative |
|
Methcathinone |
2-(Methylamino)Propiophenone |
B |
1 |
Stimulant |
|
Methenolone |
|
C |
4 Pt 2 |
Steroid |
|
Methylamphetamine |
Methamphetamine; |
A |
2 |
stimulant |
SI 2006/3331: moved methamphetamine from Class B to Class A |
Methyldesorphin |
|
A |
2 |
opioid |
|
Methyldihydromorphine (6-methyldihydromorphine) |
|
A |
2 |
Opioid |
|
Methylecgonidine |
|
A |
2 |
Cocaine derivative |
|
Methylegonine Base & HCL |
|
A |
2 |
Cocaine derivative |
|
Methylenedioxy-amphetamine |
MDA |
A |
1 |
Ectsasy family |
|
Methylenedioxyethylamphetamine |
MDA |
A |
1 |
Phenylethylamine family |
|
Methylene-dioxymethyl-amphetamine |
MDMA |
A |
1 |
Phenylethylamine family |
|
Methylenedioxypyrovalerone |
MDPV |
B |
1 |
Stimulant |
SI 2010/1207 – added MMCAT, MDPV and related cathinone derivatives |
Methylphenidate |
Ritalin |
B |
2 |
Stimulant |
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection.
|
Methylphenobarbitone |
|
B |
3 |
Barbiturate |
|
Methyltestosterone |
|
C |
4 Pt 2 |
Steroid |
|
Methyprylone |
|
C |
3 |
sedative |
|
Metopon |
|
A |
2 |
Opiate |
|
Metribolone |
|
C |
4 Pt 2 |
Steroid |
|
M-Hydroxbenzaylecgonine |
|
A |
2 |
Cocaine derivative |
|
M-Hydroxycocaine, P-Hydroxycocaine |
|
A |
2 |
Cocaine derivative |
|
Mibolerone |
|
C |
4 Pt 2 |
Steroid |
|
Midazolam |
|
C |
3 |
Benzo |
|
Morpheridine |
|
A |
2 |
Opioid |
|
Morphine |
|
A |
2/5 |
Opioid |
Falls within Schedule 5 if in a preparation of medicinal opium or morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine, cannot be recovered by readily applicable means or in a yield which would constitute a risk to health. |
Morphine methobromide (& morphine N-oxide & other pentavalent nitrogen morphine derivatives) |
|
A |
2 |
Opioid |
|
Morphine3, 6-diacalte |
|
A |
1 |
Opioid |
|
Morphine-3-acetate |
|
A |
3 |
Opioid |
|
Morphine-3-B-D-Glucoride-N-Oxide |
|
A |
3 |
Opioid |
|
Morphine-3-B-D-Glucuronide |
|
A |
2 |
Opioid |
|
Morphine-6-acetate |
|
A |
3 |
Opioid |
|
Morphine-6-B-D-glucuronide-N-oxide |
|
A |
3 |
Opioid |
|
Morphine-6-Sulphate |
|
A |
2 |
Opioid |
para (4) |
Morpholinylethylmorphine |
|
B |
2/5 |
Opioid |
|
Myrophine |
|
A |
2 |
Opioid |
|
N Methyl Lysergic Acid Diethylamide |
|
A |
1 |
Hallucinogen |
|
N-(2,5-Dimethoxy-4-propylthiophenthyl)hydroxylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
N,N-diethyltryptamine |
|
A |
1 |
Hallucinogen |
|
N,N-Dimethyl-IH-Indole-3-Ethanamine |
|
A |
1 |
Hallucinogen |
|
N,N-dimethyltryptamine |
DMT |
A |
1 |
Hallucinogen |
|
Nabilone |
|
B |
2 |
Cannabinoid |
SI2009/3209 |
Nandrolone |
|
C |
4 Pt 2 |
Steroid |
|
Napthylpyrovalerone |
Naphyrone |
B |
1 |
Stimulant |
SI 2010/1833 |
N-Benzylpethidine |
|
A |
1 |
Opioid |
para(e) |
Nealbarbitone |
|
B |
3 |
Barbiturate |
|
N-ethylamphetamine |
|
C |
4 Pt 1 |
Stimulant |
|
N-Hydroxy-Methylenedioxyamphetamine HL |
|
A |
1 |
Amphetamine |
dt |
N-hydroxy-tenamphetamine |
|
A |
1 |
Amphetamine |
|
Nicocodine |
|
B |
2/5 |
Opioid |
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection. |
Nicodicodine |
6(-nicotinoyl-dihydrocodeine) |
B |
2/5 |
|
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection. |
Nicomorphine (3,6-dinicotinoyl-morphine) |
|
A |
2 |
Opioid |
|
Nimetazepam |
|
C |
4 Pt 1 |
Benzo |
|
Nitrazepam |
|
C |
4 Pt 1 |
Benzo |
|
N-Methyl-1-(3,4 methylene dioxyphenyl)-2-butananmine-1-(4-bromo-2,5-dimethoxy)-2-ethanamine |
HBDB |
A |
1(c) |
Ectsasy family |
|
N-Methyl-1-(3-4-Methylenedioxyphenyl)-2-Butanamine |
|
A |
1 |
Opioid |
para 1(c) |
N-Methylhomoveratrylamine |
|
A |
1(C) |
Hallucinogen |
|
N-Methyl-N-(alpha-methyl-3,4-methylenedioxyphenethyl) hydroxylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
N-Omega-Methyltryptamine |
|
A |
1(b) |
Hallucinogen |
|
Non-human chorionic gonadotrophin |
|
C |
4 Pt 2 |
Steroid |
Para 1(e) |
Noracymethadol |
|
A |
2 |
Opioid |
|
Norboletone |
|
C |
4 Pt 2 |
Steroid |
|
Norclostebol |
|
C |
4 Pt 2 |
Steroid |
|
Norcodeine |
|
B |
2/5 |
opioid |
Falls within Schedule 5 if in a preparation either alone or with one or more of the drugs referring to this note not being a preparation designed for administration by injection, when compounded with one or more active or inert ingredients and containing a total of not more than 100 mg of the substance or substances (calculated as base) per dosage unit or with a total of not more than 2.5% (calculated as base) in undivided preparations |
Nordiazepam |
|
C |
4 Pt 1 |
Benzo |
|
Norethandrolone |
|
C |
4 Pt 2 |
Steroid |
|
Norlevorphanol |
|
A |
2 |
Opioid |
|
Normeperidine |
|
A |
1 |
Opioid |
|
Normethadone |
|
A |
2 |
Opioid |
|
Normorphine |
|
A |
2 |
Opioid |
|
Normorphine Hemisuccinide |
|
A |
2 |
Opioid |
|
Norpipanone |
|
A |
2 |
Opioid |
|
Octane-2-Carbaldehyde-0-Methyloxine |
|
A |
2 |
|
|
O-Methyl-N-(alpha-methyl-3,4-methylenedioxyphenethyl) Hydroxylamine |
|
A |
1 |
Ectsasy family |
Added by SI 2001/3932 |
Opium: |
|
A
|
1 2/5 |
Opioid |
Falls within Schedule 5 if in a preparation of medicinal opium or
morphine containing (in either case) not more than 0.2% of morphine
calculated as anhydrous morphine base, being a preparation compounded
with one or more other active or inert ingredients in such a way
that the opium or, as the case may be, the morphine, cannot be recovered
by readily applicable means or in a yield which would constitute
a risk to health. Falls within Schedule 5 if in any powder of ipcacuanha and opium
comprising: 10% opium, in powder 10% ipecacuanha root, in powder, well mixed with 80% of any other powdered ingredient containing no controlled drug |
Oripavine |
|
C |
2 |
Opioid |
|
Ovandrotone |
|
C |
4 Pt 2 |
Steroid |
|
Oxabolone |
|
C |
4 Pt 2 |
Steroid |
|
Oxandrolone |
|
C |
4 Pt 2 |
Steroid |
|
Oxazepam |
|
C |
4 Pt 1 |
Benzo |
|
Oxazolam |
|
C |
4 Pt 1 |
Benzo |
|
Oxycodone |
Eucodal |
A |
2 |
Opiate |
|
Oxymesterone |
|
C |
4 Pt 2 |
Steroid |
|
Oxymetholone |
|
C |
4 Pt 2 |
Steroid |
|
Oxymorphone |
|
A |
2 |
Opioid |
|
Oxymorphone-3-Glucuronide |
|
A |
2 |
Opioid |
|
P.Bromophenethylamine |
|
A |
1 (c) |
Phenylethylamine family |
|
Pemoline |
|
C |
4 Pt 1 |
Opioid |
|
Pentazocine |
|
B |
3 |
Opioid |
|
Pentobarbital |
|
B |
3 |
Barbiturate |
|
Pentobarbitone |
|
B |
3 |
Barbiturate |
|
Pentobarbitone calcium |
|
B |
3 |
Barbiturate |
|
Pentobarbitone sodium |
|
B |
3 |
Barbiturate |
|
Pethidine |
Meperidine |
A |
2 |
Opioid |
|
Pethidine Intermediate A |
|
A |
2 |
Opioid |
para 1 |
P-Fluorophenethylamine |
|
A |
1 |
Phenylethylamine family |
Para 1(c) |
Phenadoxone |
|
A |
2 |
Opioid |
|
Phenampromide |
|
A |
2 |
Opioid |
|
Phenazocine |
|
A |
2 |
Opioid |
|
Phencyclidine |
PCP, Angel Dust |
A |
2 |
Dissassociative Anaesthetic |
|
Phendimetrazine |
|
C |
3 |
stimulant |
|
Phenmetrazine |
|
B |
2 |
Stimulant |
Falls within Schedule 5 if in a preparation either alone or with one or more of the drugs referring to this note not being a preparation designed for administration by injection, when compounded with one or more active or inert ingredients and containing a total of not more than 100 mg of the substance or substances (calculated as base) per dosage unit or with a total of not more than 2.5% (calculated as base) in undivided preparations |
Phenobarbital |
|
B |
3 |
Barbiturate |
|
Phenobarbitone |
Luminal |
B |
3 |
Barbiturate |
|
Phenobarbitone sodium |
|
B |
3 |
Barbiturate |
|
Phenomorphail |
|
A |
2 |
Opioid |
|
Phenoperidine |
|
A |
2 |
Opioid |
|
Phentermine |
|
C |
3 |
Stimulant |
|
Phenylethylamines & Relative Compounds |
|
A |
1 |
Ectsasy family |
Para 1(c) |
Phenylmethylbarbituric acid |
|
B |
3 |
Sedative |
|
Pholcodine |
|
B |
2/5 |
opiate |
Falls within para 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection. Falls within Schedule 5 if in a preparation either alone or with one or more of the drugs referring to this note not being a preparation designed for administration by injection, when compounded with one or more active or inert ingredients and containing a total of not more than 100 mg of the substance or substances (calculated as base) per dosage unit or with a total of not more than 2.5% (calculated as base) in undivided preparations |
P-Hydroxybenyleceonine |
|
A |
2 |
Cocaine derivative |
|
Piminodine |
|
A |
2 |
Opioid |
|
Pinazepam |
|
C |
4 Pt 1 |
Benzo |
|
Pipradrol |
|
C |
3 |
Stimulant |
|
Piritramide |
|
A |
2 |
Opioid |
|
PMS-G (Pregnant Mare Serum-Gonadotrophin) |
|
C |
4 Pt 2 |
steroid |
|
Poppy straw |
|
A |
N/A |
Opioid |
|
Potassium Clorazepate |
|
C |
4 Pt 1 |
Benzo |
|
Prasterone |
DHEA |
C |
4 Pt 2 |
Steroid |
|
Prazepam |
|
C |
4 Pt 1 |
Benzo |
|
Probarbitone calcium |
|
B |
3 |
Barbiturate |
|
Probarbitone sodium |
|
B |
3 |
Barbiturate |
|
Proheptazine |
|
A |
2 |
Opioid |
|
Properidine (1-methyl-4-phenyl-piperidine-4- carboxylic acid isopropyl ester) |
|
A |
2 |
Opioid |
|
Propetandrol |
|
C |
4 Pt 2 |
Steroid |
|
Propiram |
|
B |
2/5 |
Opioid |
Falls within Schedule 5 if in a preparation containing, per dosage unit, not more than 100 mg of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose. |
Propoxyphene |
|
C |
2 |
Opioid |
|
Propylbenzoylecganine |
|
A |
2 |
Cocaine derivative |
|
Prostanozol |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Proxibarbital |
|
B |
3 |
Barbiturate |
|
Psilocin |
Magic Mushrooms |
A |
1 |
Hallucinogen |
|
Pyrovalerone |
|
C |
4 Pt 1 |
Stimulant |
|
Quinalbarbitone |
Secobarbital |
B |
2 |
Barbiturate |
|
Quinalbarbitone sodium |
|
B |
2 |
Barbiturate |
|
Quinbolone |
|
C |
4 Pt 2 |
Steroid |
|
Racemethorphan |
|
A |
2 |
Opioid |
|
Racemoramide |
|
A |
2 |
Opioid |
|
Racemorphan |
|
A |
2 |
Opioid |
|
Raw opium |
Opium resin |
A |
1 |
Opioid |
|
Remifentanil |
|
A |
2 |
Opioid |
|
Rolicyclidine |
|
A |
1 |
Dissassociative Anaesthetic |
|
Roxibolone |
|
C |
4 Pt 2 |
Steroid |
|
Secbutobarbital |
|
B |
3 |
Barbiturate |
|
Secbutobarbitone |
|
B |
3 |
Barbiturate |
|
Secbutobarbitone sodium |
|
B |
3 |
Barbiturate |
|
Seconal Mixture |
|
B |
2 |
Sedative |
|
Silandrone |
|
C |
4 Pt 2 |
Steroid |
|
Sodium Amytal |
|
B |
3 |
Sedative |
|
Somatotropin |
|
C |
4 Pt 2 |
Steroid |
|
Somatrem |
|
C |
4 Pt 2 |
Steroid |
|
Somatropin |
Growth Hormone |
C |
4 Pt 2 |
Steroid |
|
Stanolone |
|
C |
4 Pt 2 |
Steroid |
|
Stanozolol |
Winstrol |
C |
4 Pt 2 |
Steroid |
|
Stenbolone |
|
C |
4 Pt 2 |
Steroid |
|
Sufentanil |
|
A |
2 |
Opioid |
|
Synthetic cannabinoids receptor agonists (except Nabilone) |
|
B |
1 |
Cannabinoids |
|
Talbutal |
|
B |
3 |
Barbiturate |
|
Temazepam |
|
C |
3 |
Benzo |
|
Tenocyclidine |
|
A |
1 |
Dissassociative Anaethetic |
|
Testosterone |
|
C |
4 Pt 2 |
Steroid |
|
Tetrahydrocannabinol – THC |
|
B |
1 |
Cannabinoid |
|
Tetrahydrogestrinone |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Tetrazepam |
|
C |
4 Pt 1 |
Benzo |
|
Thebacon |
acetyldihydrocodeinone |
A |
2 |
Opioid |
|
Thebaine |
|
A |
2 |
Opioid |
|
Thiomesterone |
|
C |
4 Pt 2 |
Steroid |
|
Tilidate |
Tilidinum |
A |
2 |
Opioid |
|
Trenbolone |
|
C |
4 Pt 2 |
Steroid |
|
Triazolam |
|
C |
4 Pt 1 |
Benzo |
|
Trimeperidine |
|
A |
2 |
Opioid |
|
Trimethoxyamphetamine |
|
A |
1 |
Amphetamine |
|
Tylenol no3 |
|
B |
5 |
Opioid |
|
Veramon (Barbitone – Amidopyrine comd) |
|
B |
3 |
Opioid |
|
Vinbarbitone |
|
B |
3 |
Barbiturate |
|
Vinbarbitone sodium |
|
B |
3 |
Barbiturate |
|
Vinylbital |
|
B |
3 |
Barbiturate |
|
Vinylbitone |
|
B |
3 |
Barbiturate |
|
Zeranol |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Zilpaterol |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
Ziperol |
|
B |
2 |
Opiate |
SI2009/3209 |
β,2,5-Trimethoxy-4-methylphenethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
β,3,4,5-Tetramethoxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
β-Methoxy-3,4-methylenedioxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
a,a-Dimethyl-3-4-methylenedioxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
(4-hydroxy-3-methoxy methamphetamine) |
HMMA |
A |
1 |
Amphetamine |
Analogue covered by para 1(c) |
[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone |
WIN 55,212-2 |
B |
1 |
Cannabinoid |
SI2009/3209 |
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate |
Levonantradol |
B |
1 |
Cannabinoid |
SI2009/3209 |
03-Monoacetylmorphine Oxalate |
|
A |
2 |
Opioid |
|
1-(2-Morpholinotheyl)-4-Phenylpiperidine-4-Carboxylic Acid Ethyl Ester |
|
A |
2 |
Opioid |
|
1-(3,4-Methylenedioxybenzyl) butyl(ethyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
1-(3,4-Methylenedioxybenzyl) butyl(methyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
1-(3-Chlorophenyl)piperazine |
mCPP |
C |
4 Pt1 |
Stimulant |
Piperazine family |
1-(3-chloropropyl)piperazine |
CPCPP |
C |
4 Pt1 |
Stimulant |
Piperazine family |
1-(3-Methylphenyl)piperazine |
mMPP |
C |
1 |
Stimulant |
Piperazine family |
1-(3-Trifluoromethylphenyl)piperazine |
TFMPP |
C |
1 |
Stimulant |
Piperazine family |
1-(4- Methylphenyl)piperazine |
pMPP |
C |
1 |
Stimulant |
Piperazine family |
1-(4-Chlorophenyl)piperazine |
pCPP |
C |
1 |
Stimulant |
Piperazine family |
1-(4-Fluorophenyl)piperazine |
pFPP |
C |
1 |
Stimulant |
Piperazine family |
1-(4-Methoxyphenyl)piperazine |
pMeOPP |
C |
1 |
Stimulant |
Piperazine family |
1-(8-Bromobenzo[1,2-b;4,5-b]difuran-4-yl)-2-aminopropane |
Bromo-dragonfly |
A |
1 |
Phenylethylamine family |
Not listed in either MDA or Home Office list by name but covered by analogue clauses – probably. |
1,4 butanediol (1,4 BD) (for human ingestion) |
|
C |
|
|
SI2009/3209 |
1,4-Dibenzylpiperazine |
DBZP |
C |
1 |
Stimulant |
Piperazine family |
1:3-Dimethyl-4-phenyl-4-propionyloxy-azacycloheptane |
|
A |
2 |
|
|
1-Androstenediol |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
1-Androstenedione |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
1-Benzyl-4-methylpiperazine |
BZMP |
C |
1 |
Stimulant |
Piperazine family |
1-benzylpiperazine |
BZP |
C |
1 |
Stimulant |
Piperazine family |
1-methyl-4-phenylpiperidine-4-carboxylic acid |
|
A |
2 |
Opioid |
|
1-methyl-4-phenyl-piperidine-4-carboxylic acid isopropyl ester (properidine) |
|
A |
2 |
Opioid |
|
1-phenylpropanecarboxylic acid ethyl ester |
|
A |
2 |
Opioid |
|
2 (2-Methoxyphenyl) Ethylamine |
|
A |
1 para 3 |
Phenylethylamine family |
|
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(1,4-Dimethoxy-2-naphthyl)ethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(1,4-Methano-5,8-dimehtoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(1,4-Methano-5,8-dimehtoxy-1,2,3,4-tetrahydro-6-naphthyl)methylethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(2-Bromo-3,4-Dimethoxyphenyl) ethylamine |
|
A |
1 |
Phenylethylamine family |
para 1(c) |
2-(2-Chloro-3,4-Dimethoxyphenyl) ethylamine |
|
A |
1 |
Phenylethylamine family |
para 1(c) |
2(3,4-dimethoxyphennyl)ethylamine |
|
A |
1 |
Phenylethylamine family |
para 1(c) |
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(4-meltoxyphengl)-Ethylamine |
|
A |
1 |
Phenylethylamine family |
para 1(c) |
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[beta]furan-6-yl) -1-Methylethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[beta]furan-6-yl) -1-methylethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine |
2cb-fly |
A |
1 |
Phenylethylamine family |
|
2-(alpha-Methyl-3,4-methylenedioxyphenethylamino)ethanol |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-(P.Chlorophenyl) Ethylamine |
|
A |
1 |
Phenylethylamine family |
|
2,3 and 4 Chlorophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
2-,3 and 4 Fluorophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
2,3 and 4 Methoxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
2,4-Dichlorophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (d) |
2,5-Dimethoxy-4-Bromoamphetamine |
DOB |
A |
1 |
Amphetamine family |
|
2,5-dimethoxy-4-bromophenethylamine |
2C-B |
A |
1 |
Phenylethylamine family |
Not listed in either MDA or Home Office list by name but covered by analogue clauses |
2,5-dimethoxy-4-iodoamphetamine hydrobromide |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
2,5-Dimethoxy-4-Iodoamphetamone HCL |
|
A |
1 |
Amphetamine family |
para 1 (c) |
2,5-dimethoxy-4-iodophenylethylamine |
2C-I |
A |
1 |
Phenylethylamine family |
Not listed in either MDA or Home Office list by name but covered by analogue clauses |
2,5-Dimethoxy-4-Methylamphetamine HCL |
|
B |
1 |
Amphetamine family |
|
2,5-dimethoxy-, 4-dimethylphenethylamine |
|
A |
1 |
Phenylethylamine family |
|
2,6-Dichlorophenethylamine |
|
A |
1 |
|
para 1 (d) |
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol |
|
A |
1 |
|
Added by SI 2001/3932 |
2-Amino-1-(3,4-dimethoxyphenyl)ethanol |
|
A |
1 |
|
Added by SI 2001/3932 |
2-Beta-Carbomethoxy-3-Beta-(4-Iodophenyl) Tropane |
|
A |
2 |
Cocaine analogue |
|
2-Bromophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
2-Chloro-6-fluorophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1(d) |
2C-T-7 (2,5-dimethoxy-4-(n)-propylthiophenethylamine) |
Blue Mystic |
A |
1 |
Phenylethylamine family |
para 1 (d) |
2-Methoxyethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one |
bk-MBDBbutylone |
B |
1 |
Stimulant |
SI2010/1207 |
2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one |
bk-MDMAmethylone |
B |
1 |
Stimulant |
SI2010/1207 |
3-(0-Carboxymethyl)Morphine |
|
A |
2 |
Opioid |
|
-3-(3,4-dichlorophenyl)-8-aza-bicyclo(3.2.1)octane-2-carbaldehyde-0-methyloxime |
|
A |
2 |
Cocaine derivative |
|
3-(3,4-Dichlorophenyl)-8-Methyl-8-Aza-Bicyclo(3.2.1) |
|
A |
2 |
Cocaine derivative |
|
3,4-Dichlorophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (d) |
3,4-dimethoxy-17-methylmorphinan-6, 14-diol |
drotebanol |
A |
2 |
Opioid |
|
3,4-Dimethoxyamphetamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
3,4-Di-Methoxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
3,4-methylenedioxy-amphetamine |
MDA |
A |
1 |
Phenylethylamine family |
|
3,4-methylenedioxymethamphetamine Hydrochloride |
MDMA |
A |
1 |
Phenylethylamine family |
para 1 (c) |
3,4-methylenedioxy-N, N-dimethylamphetamine |
|
A |
1 |
Phenylethylamine family |
|
3,6-dinicotinoyl-morphine |
nicomorphine |
A |
2 |
Opioid |
|
3-benzylmorphine |
benzylmorphine |
A |
2 |
Opioid |
|
3-Bromophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
3-Carboxymetlyl Morphine |
|
A |
2 |
Opioid |
|
3–Dimethylheptyl–11–hydroxyhexahydrocannabinol |
HU-243 |
B |
1 |
Cannabinoid |
SI2009/3209 |
3-Fluoromethcathinone |
4-FMC |
B |
1 |
Stimulant |
SI2010/1207 |
3-Hydroxy-4-methoxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
3-Hydroxy-5αandrostan-17-one |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
3-Hydroxy-N-Methylmorphinain |
|
A |
2 |
Opioid |
|
3-Hydroxy-N-methylmorphinar |
|
A |
2 |
Opioid |
|
3-Hydroxy-N-phenacylmorphinan |
|
A |
2 |
Opioid |
|
3-Methoxy-4-ethoxy-alpha-methylphethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
3-Methoxy-4-Hydroxyamphetamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
3-Methoxy-4-Hydroxymethamphetamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
3-Methoxy-4-Hydroxyphenethylamine |
|
A |
1 para 1 |
Phenylethylamine family |
para 1 (c) |
3-Methyfentanyl Hydrochloride |
|
A |
1 |
Opioid |
Para 1(d) |
4-Bromo-2,5, Dimethoxy Phenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c ) |
4-Bromo-2,5-Dimethoxyphene Thylamine |
|
A |
1 |
Phenylethylamine family |
(c) |
4-bromo-2,5-dimethoxy-x-methylphenethylamine |
|
A |
1 |
Phenylethylamine family |
|
4-Bromo-Beta,2,5-trimethoxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
4-Bromophenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
4-chloromethandienone |
|
C |
4 Pt 2 |
Steroid |
|
4-cyano-1-methyl-4-phenylpiperidine |
|
A |
2 |
Opioid |
|
4-cyano-2-dimethylamino-4,4-diphenylbutane |
|
A |
2 |
Opioid |
|
4-Dimethylamino-1:2-Diphenyl-3-Methy-2-Propionyloxybutane |
|
C |
2 |
opiate |
|
4-hydroxy-3-methoxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
4-Iodo-2,5-dimethoxy-Alpha-methylphenethyl(dimethyl)amine |
|
A |
1 |
Phenylethylamine family |
Added by SI 2001/3932 |
4-Methoxymethcathinone |
bk-PMMAmethedrone |
B |
1 |
Stimulant |
SI2010/1207 |
4-Methoxyphenethylamine |
|
A |
1 |
Phenylethylamine family |
|
4-Methoxythenylethylamine |
|
A |
1 |
Phenylethylamine family |
para 1 (c) |
|
A |
1 |
Stimulant |
|
|
4-Methylmethcathinone |
MMCAT |
B |
1 |
Stimulant |
SI2010/1207 |
4-Methylthioamphetamine |
|
A |
1 |
Phenylethylamine family |
|
4-phenylpiperidine-4-carboxylic acid ethyl ester |
|
A |
2 |
Opioid |
|
5 ethyl-5-n-nonyl barbitonic acid |
|
B |
3 |
Barbiturate |
|
5-Androstenedione |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
5-Methoxydimethyltryptamine |
|
A |
1 |
Hallucinogen |
(b) |
5α-Androstane-3,17-diol |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
6-Acetylmorphine Hydrochloride |
|
A |
2 |
Opioid |
|
6-Beta-Hydroxytestosterone |
|
C |
4 Pt2 |
Steroid |
|
6-methyldihydromorphine |
methyldihydromorphine |
A |
2 |
Opioid |
|
6-nicotinoyldihydrocodeine (nicodicodine) |
|
B |
2/5 |
Opioid |
|
7 Alpha, 17 Alpha-Dimethyl-19-Nortesterone |
|
C |
4 Pt2 |
Steroid |
|
9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol |
HU-210 |
B |
1 |
Cannabinoid |
SI2009/3209 |
14-Hydroxydihydromorphine |
|
A |
2 |
Opioid |
|
14-Hydroxymorphine |
|
A |
2 |
Opioid |
|
19-Norandrostenedione |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
19-Norandrosterone |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
19-Noretiocholanolone |
|
C |
4 Pt2 |
Steroid |
SI2009/3209 |
19-Nortestosterone |
|
C |
4 Pt 2 |
Steroid |
|